View ValuationDarwin 将来の成長Future 基準チェック /56Darwin利益と収益がそれぞれ年間123%と25.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に7.4% 121.8%なると予測されています。主要情報123.0%収益成長率121.85%EPS成長率Biotechs 収益成長22.9%収益成長率25.8%将来の株主資本利益率7.40%アナリストカバレッジLow最終更新日21 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • 10hDarwin AG announces Annual dividend, payable on July 01, 2026Darwin AG announced Annual dividend of EUR 0.5600 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.お知らせ • May 22Darwin AG, Annual General Meeting, Jun 26, 2026Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time.New Risk • May 15New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 7.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.9% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin).Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.Valuation Update With 7 Day Price Move • Mar 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €7.90, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year.お知らせ • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026New Risk • Feb 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change).Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €9.50, the stock trades at a forward P/E ratio of 36x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 44% over the past year.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.45, the stock trades at a forward P/E ratio of 31x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 56% over the past year.New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).New Risk • Dec 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€78.6m market cap, or US$91.3m).Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 33%After last week's 33% share price gain to €7.90, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 20x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past year.New Risk • Sep 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€70.2m market cap, or US$82.7m).New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €87.6m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€87.6m market cap, or US$100.0m).Upcoming Dividend • Jun 23Upcoming dividend of €2.25 per shareEligible shareholders must have bought the stock before 30 June 2025. Payment date: 02 July 2025. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 7.0%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (2.2%).お知らせ • May 21+ 1 more updateDarwin AG, Annual General Meeting, Jun 27, 2025Darwin AG, Annual General Meeting, Jun 27, 2025, at 13:30 W. Europe Standard Time.New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.2m).お知らせ • May 14Darwin AG, Annual General Meeting, Jun 18, 2024Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.業績と収益の成長予測XTRA:7V0 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028137N/A-11N/A212/31/2027897-143212/31/2026590-17-3112/31/2025621-22-13N/A12/31/20242718-29-25N/A12/31/2023180-20-19N/A12/31/2022210459395N/A12/31/2021133231112N/Aアナリストによる今後の成長予測収入対貯蓄率: 7V0の予測収益成長率 (年間123% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: 7V0の収益 ( 123% ) はGerman市場 ( 17.1% ) よりも速いペースで成長すると予測されています。高成長収益: 7V0の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 7V0の収益 ( 25.8% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 7V0の収益 ( 25.8% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7V0の 自己資本利益率 は、3年後には低くなると予測されています ( 7.4 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 07:55終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Darwin AG 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Cosmin FilkerGBC AGKlaus BreitenbachODDO BHF Corporate & Markets
お知らせ • 10hDarwin AG announces Annual dividend, payable on July 01, 2026Darwin AG announced Annual dividend of EUR 0.5600 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.
お知らせ • May 22Darwin AG, Annual General Meeting, Jun 26, 2026Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time.
New Risk • May 15New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 7.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.9% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin).
Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
Valuation Update With 7 Day Price Move • Mar 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €7.90, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year.
お知らせ • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026
New Risk • Feb 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change).
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €9.50, the stock trades at a forward P/E ratio of 36x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 44% over the past year.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.45, the stock trades at a forward P/E ratio of 31x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 56% over the past year.
New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
New Risk • Dec 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€78.6m market cap, or US$91.3m).
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 33%After last week's 33% share price gain to €7.90, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 20x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past year.
New Risk • Sep 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€70.2m market cap, or US$82.7m).
New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €87.6m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€87.6m market cap, or US$100.0m).
Upcoming Dividend • Jun 23Upcoming dividend of €2.25 per shareEligible shareholders must have bought the stock before 30 June 2025. Payment date: 02 July 2025. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 7.0%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (2.2%).
お知らせ • May 21+ 1 more updateDarwin AG, Annual General Meeting, Jun 27, 2025Darwin AG, Annual General Meeting, Jun 27, 2025, at 13:30 W. Europe Standard Time.
New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.2m).
お知らせ • May 14Darwin AG, Annual General Meeting, Jun 18, 2024Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.